XML 76 R10.htm IDEA: XBRL DOCUMENT v3.19.3
Cash, Cash Equivalents, Restricted Cash and Marketable Securities
9 Months Ended
Sep. 30, 2019
Investments Debt And Equity Securities [Abstract]  
Cash, Cash Equivalents, Restricted Cash and Marketable Securities

3. Cash, Cash Equivalents, Restricted Cash and Marketable Securities

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheet that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands):

 

 

September 30, 2019

 

 

December 31, 2018

 

 

September 30, 2018

 

 

December 31, 2017

 

Cash and cash equivalents

 

$

37,297

 

 

$

49,348

 

 

$

38,712

 

 

$

26,584

 

Restricted cash

 

 

619

 

 

 

619

 

 

 

622

 

 

 

629

 

Total cash, cash equivalents and restricted cash shown

   in the condensed consolidated statements of cash flows

 

$

37,916

 

 

$

49,967

 

 

$

39,334

 

 

$

27,213

 

Restricted cash balances relate to certificates of deposit issued as collateral to certain letters of credit issued as security to our facility leases. See Note 6.

Cash, cash equivalents and marketable securities consist of the following (in thousands):

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Estimated

Fair Value

 

September 30, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

$

3,565

 

 

$

-

 

 

$

-

 

 

$

3,565

 

Money market funds

 

33,732

 

 

 

-

 

 

 

-

 

 

 

33,732

 

Total cash and cash equivalents

 

37,297

 

 

 

-

 

 

 

-

 

 

 

37,297

 

Marketable securities available-for-sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasuries

 

1,495

 

 

 

2

 

 

 

-

 

 

 

1,497

 

U.S. government agency securities

 

58,718

 

 

 

23

 

 

 

(22

)

 

 

58,719

 

Corporate debt securities

 

77,399

 

 

 

42

 

 

 

(8

)

 

 

77,433

 

Total marketable securities available-for-sale

 

137,612

 

 

 

67

 

 

 

(30

)

 

 

137,649

 

Total cash, cash equivalents and marketable securities

$

174,909

 

 

$

67

 

 

$

(30

)

 

$

174,946

 

December 31, 2018

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

$

3,147

 

 

$

-

 

 

$

-

 

 

$

3,147

 

Money market funds

 

44,002

 

 

 

-

 

 

 

-

 

 

 

44,002

 

Corporate debt securities

 

2,199

 

 

 

-

 

 

 

-

 

 

 

2,199

 

Total cash and cash equivalents

 

49,348

 

 

 

-

 

 

 

-

 

 

 

49,348

 

Marketable securities available-for-sale:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasuries

 

14,732

 

 

 

-

 

 

 

(8

)

 

 

14,724

 

U.S. government agency securities

 

42,416

 

 

 

-

 

 

 

(44

)

 

 

42,372

 

Corporate debt securities

 

39,108

 

 

 

-

 

 

 

(16

)

 

 

39,092

 

Total marketable securities available-for-sale

 

96,256

 

 

 

-

 

 

 

(68

)

 

 

96,188

 

Total cash, cash equivalents and marketable securities

$

145,604

 

 

$

-

 

 

$

(68

)

 

$

145,536

 

The maturities of our marketable securities available-for-sale are as follows (in thousands):

 

 

 

September 30, 2019

 

 

 

Amortized Cost

 

 

Estimated

Fair Value

 

Mature in one year or less

 

$

117,130

 

 

$

117,178

 

Mature after one year through two years

 

 

20,482

 

 

 

20,471

 

 

 

$

137,612

 

 

$

137,649

 

 

There were no realized gains or losses from the sale of marketable securities during the nine months ended September 30, 2019 and 2018.

We have classified our entire investment portfolio as available-for-sale and available for use in current operations and accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities, with unrealized gains and losses included in accumulated other comprehensive loss in stockholders’ equity. Realized gains and losses and declines in value, if any, judged to be other than temporary on available-for-sale securities are included in interest income or expense. The cost of securities sold is based on the specific identification method. Management assesses whether declines in the fair value of investment securities are other than temporary. In determining whether a decline is other than temporary, management considers the following factors:

 

whether the investment has been in a continuous realized loss position for over 12 months;

 

the duration to maturity of our investments;

 

our intention and ability to hold the investment to maturity and if it is not more likely than not that we will be required to sell the investment before recovery of the amortized cost bases;

 

the credit rating, financial condition and near-term prospects of the issuer; and

 

the type of investments made.

To date, there have been no declines in fair value that have been identified as other than temporary.